Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Synergy Pharma: Sales Ramp Ignored
Summary
Synergy Pharma continues a slow ramp of Turlance prescriptions.
Significant cost controls helped cut the quarterly loss my nearly $10 million.
The Express Scripts deal for 2019 places the biotech on a path to a huge sales ramp by Q2'19.
Takeaway
The key investor takeaway is that Synergy Pharma remains a flawed company. The stock price is attractive around $1.75 as the market sees the company as irreversibly harmed, yet the new management team continues to build on recent successes. The risks remain high as the biotech needs additional script ramps to even approach cash flow breakeven and the company needs additional funds to survive. The odds still remain in favor of owning the stock due to strong expectations for a big ramp into Q2 next year
https://seekingalpha.com/article/4199100-synergy-pharma-sales-ramp-ignored
Re: Farmas USA
Re: Farmas USA
Re: Farmas USA
Esa es la gran pregunta cuya respuesta , no termina de materializarse con mi opinión .....jjj .....soy de los que cree que vamos a la paridad , pero de momento no llega, ......eso sí , en estos momentos mis $ los tengo comprados a +_1,20, quien sabe , igual en el momento que se acerque la paridad , sea momento de vender toda mi cartera en $, y recoger beneficios , tanto de las CELG y TSRO, como de los $ de mi cuenta de Divisas ...y esperar ese gran crack que anuncian los estudiosos , y viendo los últimos acontecimientos , empiezo a tener la mosca detrás de la oreja ....🤔